Aurinia Pharmaceuticals R&D spend
Aurinia Pharmaceuticals Inc. · AUPH (NASDAQ) · Victoria, BC · Pharmaceuticals
Latest R&D (CAD)
$45.4M
Period ended 2025-12-31
Revenue (CAD)
$395.7M
11.5% of revenue · scale $134.1M
R&D by fiscal period
2025
$45.4M
2024
$28.5M
2023
$67.0M
2022
$58.5M
2021
$64.1M
2020
$67.5M
2019
$70.1M
2018
$53.6M
| Period end | R&D (CAD) | Revenue (CAD) | Native R&D | Form | Source |
|---|---|---|---|---|---|
| 2025-12-31 | $45,435,489 | $395,654,279 | $32,505,000 USD | 10-K | SEC EDGAR |
| 2024-12-31 | $28,471,293 | $322,085,183 | $20,785,000 USD | 10-K | SEC EDGAR |
| 2023-12-31 | $67,000,458 | $236,889,896 | $49,641,000 USD | 10-K | SEC EDGAR |
| 2022-12-31 | $58,542,884 | $174,413,239 | $44,988,000 USD | 10-K | SEC EDGAR |
| 2021-12-31 | $64,102,737 | $57,165,868 | $51,139,000 USD | 10-K | SEC EDGAR |
| 2020-12-31 | $67,513,671 | $67,233,297 | $50,327,000 USD | 10-K | SEC EDGAR |
| 2019-12-31 | $70,147,895 | $421,954 | $52,866,000 USD | 10-K | SEC EDGAR |
| 2018-12-31 | $53,618,657 | $599,909 | $41,382,000 USD | 10-K | SEC EDGAR |